Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adverum Biotechnologies, Inc. (ADVM : NSDQ)

• Company Description    Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Number of Employees: 155

• Price / Volume Information    Yesterday's Closing Price: $2.54 Daily Weekly Monthly 20 Day Moving Average: 298,627 shares Shares Outstanding: 20.89 (millions) Market Capitalization: $53.06 (millions) Beta: 0.70 52 Week High: $10.14 52 Week Low: $1.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.25% -1.41% 12 Week -13.31% -26.84% Year To Date -45.61% -48.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 CARDINAL WAY - Redwood City,CA 94063 USA ph: 650-656-9323 fax: 650-329-8151 areddi@adverum.com http://www.adverum.com

• General Corporate Information    Officers Laurent Fischer - President and Chief Executive Officer Patrick Machado - Chairman of the Board Linda Rubinstein - Chief Financial Officer Soo Hong - Director James Scopa - Director Peer Information Adverum Biotechnologies, Inc. (CORR.) Adverum Biotechnologies, Inc. (RSPI) Adverum Biotechnologies, Inc. (CGXP) Adverum Biotechnologies, Inc. (BGEN) Adverum Biotechnologies, Inc. (GTBP) Adverum Biotechnologies, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00773U207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 20.89 Most Recent Split Date: 3.00 (0.10:1) Beta: 0.70 Market Capitalization: $53.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: -14.80% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -130.53 12/31/24 - -78.80 ROA 06/30/25 - - 03/31/25 - -66.31 12/31/24 - -47.58 Current Ratio 06/30/25 - - 03/31/25 - 3.57 12/31/24 - 5.73 Quick Ratio 06/30/25 - - 03/31/25 - 3.57 12/31/24 - 5.73 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -15,079.90 12/31/24 - -13,092.70 Book Value 06/30/25 - - 03/31/25 - 1.26 12/31/24 - 3.40 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©